CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Vijay Pande, founding partner of a16z bio and health strategy, steps down

From TechCrunch

By Marina Temkin

June 10, 2025

Vijay Pande, founding partner of a16z bio and health strategy, steps down

Vijay Pande, founding partner of a16z bio and health strategy, steps down

Vijay Pande, a general partner at Andreessen Horowitz who founded the firm’s a16z Bio + Health strategy, announced that he is stepping down from his role.

Since its founding in 2014, a16z Bio + Health has raised four funds, including a $1.5 billion fund that closed in 2022. However, it’s now seeking a much smaller $750 million fifth fund, The Wall Street Journal reported. In January, a16z Bio + Health announced that it will separately manage a $500 million biotech fund funded by pharmaceutical giant Eli Lilly.

a16z Bio + Health backs digital health startups and companies at the intersection of AI, computation, and biology.

Pande’s investments include Devoted Health, an individualized medical plan provider; Function Health, a personalized lab testing startup; and Freenome, a company aiming to detect cancer through blood draws. Before joining Andreessen Horowitz, Pande was a professor of chemistry, structural biology, and computer science at Stanford University.

The remaining partners on the a16z Bio + Health team are Jorge Conde, Julie Yoo, and Vineeta Agarwala.

View original article on techcrunch.com

Most Recent

Microsoft tests fix for latest hours-long Outlook outage

Microsoft says it's testing a fix for the widespread Outlook issues that have led to email delays and failures.

Sep 1, 2026

Bluesky adds an 'algorithmic opt-out' feature for those who don't want to go viral

Sometimes people just want to post to their followers, Bluesky says.

Aug 28, 2026

Hoomanely’s building a smart feeding bowl and an AI platform to help owners spot when their pup is sick

Hoomanely has developed a smart bowl to measure and record dogs' feeding data, then tells owners if behaviors change.

Aug 27, 2026

Viral AI startup Instinct has raised $350M at a $2.5B valuation

TechCrunch reported that Instinct closed a $250 million Series B co-led by Index Ventures and Benchmark at a $2.5 billion valuation, bringing total funding to roughly $350 million. The article traces the assistant rapid adoption among Silicon Valley users.

Aug 25, 2026

Similar Posts

a16z brings growth fund to $8.5B days after launching new $1.1B fund

Venture capital firm Andreessen Horowitz has expanded its fifth growth fund to $8.5 billion. That means the firm added another $1.75 billion since the fund launched in January with $6.75 billion. The firm’s announcement comes just days after a16z announced it had raised a fresh $1.1 billion for a ne

Aug 31, 2026

Obvious Ventures lands fund five with a 360-degree view of planetary, human, economic health

The 12-year-old firm raised $360,360,360 for its fifth fund. And there's a reason for that number.

Jan 26, 2026

a16z pauses its famed TxO Fund for underserved founders, lays off staff

Andreessen Horowitz is pausing its Talent x Opportunity (TxO) fund and program, according to multiple sources.

Nov 3, 2025

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners closed its second fund, raising $82 million. It hopes to invest in at least 25 early-stage companies, writing check sizes between $1 million and $2.3 million, with 50% of the fund reserved for follow-on investments.

May 29, 2025